Treatment with DPP-4I Anagliptin or α-GI Miglitol Reduces IGT Development and the Expression of CVD Risk Factors in OLETF Rats.

@article{Imai2015TreatmentWD,
  title={Treatment with DPP-4I Anagliptin or α-GI Miglitol Reduces IGT Development and the Expression of CVD Risk Factors in OLETF Rats.},
  author={Chihiro Imai and Tomomi Harazaki and Seiya Inoue and Kazuki Mochizuki and Toshinao Goda},
  journal={Journal of nutritional science and vitaminology},
  year={2015},
  volume={61 4},
  pages={
          313-21
        }
}
It has been reported that postprandial hyperglycemia from the pre-diabetic stage, especially from the impaired glucose tolerance (IGT) stage, is positively associated with subsequent incidences of cardiovascular diseases (CVD) and type 2 diabetes. In this study, we aimed to investigate whether treatment with a dipeptidyl peptidase-4 inhibitor (DPP-4I) or an α-glucosidase inhibitor (α-GI), either of which suppresses postprandial hyperglycemia, reduces the expression of CVD risk factors in an IGT… CONTINUE READING
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

Similar Papers

Loading similar papers…